PROTHENA CORPORATION PUBLIC LIMITED COMPANY APIC, Share-based Payment Arrangement, Increase for Cost Recognition
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $7.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $7.88M, a 36.56% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $6.92M, a 36.84% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $7.20M, a 34.67% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $12.42M, a 3.13% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $37.64M, a 18.11% decline from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $45.96M, a 12.34% increase from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $40.91M, a 30.62% increase from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $31.32M, a 27.03% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.88M 10-Q · filed 2026-08-06 | $14.79M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $6.92M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $37.64M 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $7.20M 10-Q · filed 2025-11-06 | $19.62M derived: sum of 2 quarters · filed 2026-08-06 | $30.57M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $12.42M 10-Q · filed 2026-08-06 | $23.37M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $10.95M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $45.96M 10-K · filed 2026-02-27 | |||
| 2024-09-30 | $11.02M 10-Q · filed 2025-11-06 | $23.06M derived: sum of 2 quarters · filed 2025-11-06 | $35.44M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $12.04M 10-Q · filed 2025-11-06 | $24.42M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $12.38M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $40.91M 10-K · filed 2026-02-27 | |||
| 2023-09-30 | $10.94M 10-Q · filed 2024-11-12 | $21.04M derived: sum of 2 quarters · filed 2024-11-12 | $29.83M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $10.10M 10-Q · filed 2024-11-12 | $18.89M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $8.79M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $31.32M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $7.97M 10-Q · filed 2023-11-02 | $16.23M derived: sum of 2 quarters · filed 2023-11-02 | $23.89M derived: sum of 3 quarters · filed 2023-11-02 | $30.78M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $8.26M 10-Q · filed 2023-11-02 | $15.92M derived: sum of 2 quarters · filed 2023-11-02 | $22.81M derived: sum of 3 quarters · filed 2024-02-22 | $28.86M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $7.66M 10-Q · filed 2023-11-02 | $14.55M derived: sum of 2 quarters · filed 2024-02-22 | $20.60M derived: sum of 3 quarters · filed 2024-02-22 | $26.14M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $6.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $12.94M derived: sum of 2 quarters · filed 2024-02-22 | $18.48M derived: sum of 3 quarters · filed 2024-02-22 | $24.66M 10-K · filed 2024-02-22 |
| 2021-09-30 | $6.05M 10-Q · filed 2022-11-03 | $11.60M derived: sum of 2 quarters · filed 2022-11-03 | $17.77M 10-Q · filed 2021-11-04 | $22.98M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $5.54M 10-Q · filed 2022-11-03 | $11.72M 10-Q · filed 2021-08-05 | $16.92M derived: sum of 3 quarters · filed 2023-02-28 | $22.51M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $6.18M 10-Q · filed 2022-11-03 | $11.38M derived: sum of 2 quarters · filed 2023-02-28 | $16.97M derived: sum of 3 quarters · filed 2023-02-28 | $22.65M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $5.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $10.79M derived: sum of 2 quarters · filed 2023-02-28 | $16.48M derived: sum of 3 quarters · filed 2023-02-28 | $22.01M 10-K · filed 2023-02-28 |
| 2020-09-30 | $5.58M 10-Q · filed 2021-11-04 | $11.27M derived: sum of 2 quarters · filed 2021-11-04 | $16.81M 10-Q · filed 2021-11-04 | $22.09M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $5.69M 10-Q · filed 2021-08-05 | $11.22M 10-Q · filed 2021-08-05 | $16.51M derived: sum of 3 quarters · filed 2022-02-25 | $22.33M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $5.54M 10-Q · filed 2021-05-11 | $10.82M derived: sum of 2 quarters · filed 2022-02-25 | $16.64M derived: sum of 3 quarters · filed 2022-02-25 | $22.92M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $5.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $11.10M derived: sum of 2 quarters · filed 2022-02-25 | $17.38M derived: sum of 3 quarters · filed 2022-02-25 | $23.59M 10-K · filed 2022-02-25 |
| 2019-09-30 | $5.82M 10-Q · filed 2019-11-05 | $12.09M derived: sum of 2 quarters · filed 2019-11-05 | $18.30M 10-Q · filed 2019-11-05 | $24.11M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $6.28M 10-Q · filed 2019-08-06 | $12.48M 10-Q · filed 2019-08-06 | $18.29M derived: sum of 3 quarters · filed 2021-02-26 | $25.33M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $6.21M 10-Q · filed 2019-05-07 | $12.01M derived: sum of 2 quarters · filed 2021-02-26 | $19.06M derived: sum of 3 quarters · filed 2021-02-26 | $25.36M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $12.85M derived: sum of 2 quarters · filed 2021-02-26 | $19.16M derived: sum of 3 quarters · filed 2021-02-26 | $26.06M 10-K · filed 2021-02-26 |
| 2018-09-30 | $7.04M 10-Q · filed 2019-11-05 | $13.35M derived: sum of 2 quarters · filed 2019-11-05 | $20.25M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $6.31M 10-Q · filed 2019-08-06 | $13.21M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $6.90M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $26.76M 10-K · filed 2020-03-03 | |||
| 2016-12-31 | $24.93M 10-K · filed 2019-03-15 | |||
| 2015-12-31 | $10.41M 10-K · filed 2018-02-26 | |||
| 2014-12-31 | $5.60M 10-K · filed 2017-02-27 | |||
| 2013-12-31 | $3.13M 10-K · filed 2016-02-25 | |||
| 2012-12-31 | $6.10M 10-K · filed 2015-03-13 | |||
| 2011-12-31 | $2.97M 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |